Could a migraine drug help Alzheimer's patients?
NCT ID NCT07323927
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This small early-phase study is testing whether galcanezumab, a drug used for migraines, can help people with mild-to-moderate Alzheimer's disease. Ten participants will receive injections over 24 weeks, and researchers will measure changes in thinking, memory, and brain chemicals. The goal is to see if the drug is safe and might ease symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xuanwu Hospital, Capital Medical University
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking thousands of dementia cases reshape how we care for patients?
- PET scans probe link between brain inflammation and Alzheimer's damage
- Can sound waves soothe Dementia's emotional turmoil?
- Can a Low-Dose immune calmer slow Alzheimer's decline?
- A stumble before memory slips? study tests if falls predict Alzheimer's
- The eyes as a window to the brain: can a simple scan monitor MS, Alzheimer's, and Parkinson's?